Acer Therapeutics Announces Initiation of Its Pivotal Phase III DiSCOVER Trial of EDSIVO™ (Celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome

Acer Therapeutics, Inc. announced the initiation of patient screening in its Phase III DiSCOVER (Decentralized Study of Celiprolol on vEDS-related Event Reduction) clinical trial of EDSIVO™ (celiprolol) for the treatment of patients with COL3A1-positive vascular Ehlers-Danlos Syndrome.